.svg.png){kind=small}
FOX - Resverlogix: Dedicated to Improving the Lives of Patients with Chronic Illnesses
.svg){kind=small}
The future of drug development
Resverlogix is committed to developing epigenetic therapies for the benefit of patients with chronic disease. Their current clinical program focuses on advancing their lead compound (apabetalone) and evaluating its therapeutic potential in the treatment of vascular disease and COVID-19.
Resverlogix Corp. (“Resverlogix” or the “Company”), founded in 2001 by Donald McCaffrey and Norman Wong, is a late-stage clinical biotechnology company dedicated to improving the lives of patients with chronic illnesses. We provide novel science, clinical and value-based health solutions to key stakeholders such as pharmaceutical, physician, and health payer groups. In 2005, Resverlogix commenced trading on the TSX under the symbol RVX.
For more information on Resverlogix Corp. (TSX: RVX) please click the investor request info button.
.png){kind=small}
